These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 9498162

  • 21. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
    Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.
    Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
    [Abstract] [Full Text] [Related]

  • 22. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P, Barni S, Tancini G, Brivio F, Tisi E, Zubelewicz B, Braczkowski R.
    J Biol Regul Homeost Agents; 1994 Jun; 8(4):126-9. PubMed ID: 7660855
    [Abstract] [Full Text] [Related]

  • 23. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Jun; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 24. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G.
    J Biol Regul Homeost Agents; 1997 Jun; 11(4):157-9. PubMed ID: 9582617
    [Abstract] [Full Text] [Related]

  • 25. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P, Ardizzoia A, Tisi E, Rossini F, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1993 Jun; 7(1):34-6. PubMed ID: 8346714
    [Abstract] [Full Text] [Related]

  • 26. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A.
    Oncology; 1995 Jun; 52(2):163-6. PubMed ID: 7854778
    [Abstract] [Full Text] [Related]

  • 27. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 28. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
    Lissoni P, Malugani F, Bukovec R, Bordin V, Perego M, Mengo S, Ardizzoia A, Tancini G.
    Neuro Endocrinol Lett; 2003 Jan; 24(1-2):83-5. PubMed ID: 12743539
    [Abstract] [Full Text] [Related]

  • 29. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P.
    Anticancer Res; 2003 Jan; 23(2C):1951-4. PubMed ID: 12820485
    [Abstract] [Full Text] [Related]

  • 30. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression.
    Brivio F, Fumagalli L, Fumagalli G, Pescia S, Brivio R, Di Fede G, Rovelli F, Lissoni P.
    In Vivo; 2010 Jan; 24(2):239-41. PubMed ID: 20364003
    [Abstract] [Full Text] [Related]

  • 31. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1991 Jan; 5(4):154-6. PubMed ID: 1803863
    [Abstract] [Full Text] [Related]

  • 32. Melatonin as biological response modifier in cancer patients.
    Neri B, de Leonardis V, Gemelli MT, di Loro F, Mottola A, Ponchietti R, Raugei A, Cini G.
    Anticancer Res; 1998 Jan; 18(2B):1329-32. PubMed ID: 9615811
    [Abstract] [Full Text] [Related]

  • 33. Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones.
    Lissoni P, Messina G, Rovelli F.
    Curr Aging Sci; 2012 Dec; 5(3):231-5. PubMed ID: 23451999
    [Abstract] [Full Text] [Related]

  • 34. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
    Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F.
    Nat Immun; 1998 Dec; 16(1):27-33. PubMed ID: 9789122
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
    Lissoni P, Barni S, Cazzaniga M, Ardizzoia A, Rovelli F, Brivio F, Tancini G.
    Oncology; 1994 Dec; 51(4):344-7. PubMed ID: 8208518
    [Abstract] [Full Text] [Related]

  • 36. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L.
    Anticancer Res; 2001 Dec; 21(1B):777-9. PubMed ID: 11299843
    [Abstract] [Full Text] [Related]

  • 37. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio F, Piperno A, Aldeghi R, Fossati D.
    Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms.
    Lissoni P, Ardizzoia A, Barni S, Brivio F, Tisi E, Rovelli F, Tancini G, Maestroni G, Fumagalli L.
    Oncol Rep; 1995 Nov; 2(6):1063-8. PubMed ID: 21597854
    [Abstract] [Full Text] [Related]

  • 39. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L.
    Oncol Rep; 2002 Nov; 9(4):887-96. PubMed ID: 12066227
    [Abstract] [Full Text] [Related]

  • 40. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
    Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S.
    Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.